Tasigna

Phase 2Small molecule

Novartis

Tasigna is one of 74 small molecule programs targeting Chronic Myelogenous Leukemia. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Chronic Myelogenous LeukemiaUnknown

SynovitisActive, not recruiting

Plexiform NeurofibromaActive, not recruiting

Chronic Myelogenous LeukemiaPreclinical

Unknown

SynovitisPhase 2

Active, not recruiting

Plexiform NeurofibromaPhase 1

Active, not recruiting

Competition

Competitive Landscape

120 competitors in Chronic Myelogenous Leukemia

#DrugCompanyPhaseTrials

Cytosar

Teva

Phase 3

20 2

Leukine

Sanofi

Phase 3

8 3

Idamycin

Pfizer

Phase 3

8 4

Scemblix

Novartis

Phase 3

4 5

Cytoxan

BBaxter Healthcare Corporation

Phase 3

13 6

Busulfex

Akero Therapeutics

Phase 3

13 7

Droxia

TTheravia

Phase 3

7 8

Vepesid

AAvyxa

Phase 3

7 9

PEG-Intron

Gleevec

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

MPA1 trial

Pharmacokinetic Comparison of XS003 and Tasigna

Completed·XXSpray Microparticles·Phase 1·NCT02068898·27 enrolled

Synovitis1 trial

Study of Nilotinib Efficacy in Pigmented Villo-Nodular Synovitis/ Tenosynovial Giant Cell Tumour (PVNS/TGCT)

Completed·CCentre Leon Berard·Phase 2·NCT01261429·50 enrolled

Pregnancy1 trial

A Global Imatinib and Nilotinib Pregnancy Exposure Registry

Completed· Novartis logo

Novartis··NCT01289054·4 enrolled

Metabolism1 trial

To Evaluate the Effects of Multiple Doses of Nilotinib on the Pharmacokinetics and Metabolism of Midazolam in CML Patients With Additional Extension Phase to Evaluate the Safety of Nilotinib

Completed· Novartis logo

Novartis·Phase 1·NCT01223898·19 enrolled

Plexiform Neurofibroma1 trial

Study of Tasigna®/Nilotinib (AMN107) in Neurofibromatosis (NF1) Patients With Plexiform Neurofibromas

Completed·IIndiana University·Phase 1·NCT01275586·6 enrolled

1 more indication

Adult1 trial

A Bioavailability Study of Nilotinib in Healthy, Adult, Human Subjects Under Fasted Conditions.

Completed·XXspray Pharma AB·Phase 1·NCT07138378·128 enrolled

Sources

References

[1]
ClinicalTrials.gov — 6 trial records for Tasigna. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Tasigna compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Tasigna. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Novartis company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: Novartis

Tasigna

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

MPA1 trial

Synovitis1 trial

Pregnancy1 trial

Metabolism1 trial

Plexiform Neurofibroma1 trial

Adult1 trial

References

Drug Info

Quick Facts

Related News